Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.

Rosenfeld, Philip J; Schwartz, Steven D; Blumenkranz, Mark S; Miller, Joan W; Haller, Julia A; Reimann, James D; Greene, William L; Shams, Naveed

Rosenfeld, Philip J; Schwartz, Steven D; Blumenkranz, Mark S; Miller, Joan W; Haller, Julia A; Reimann, James D; Greene, William L; Shams, Naveed.

Affiliation

Rosenfeld PJ; Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miami, Florida 33136, USA. prosenfeld@med.miami.edu

Ophthalmology ; 112(6): 1048-53, 2005 Jun.

Article in En | MEDLINE | ID: mdl-15885778

Subject(s)

Antibodies, Monoclonal/administration & dosage; Choroidal Neovascularization/drug therapy; Immunoglobulin Fragments/immunology; Macular Degeneration/drug therapy; Vascular Endothelial Growth Factor A/immunology; Aged; Aged, 80 and over; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal, Humanized; Choroidal Neovascularization/diagnosis; Choroidal Neovascularization/etiology; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration/complications; Macular Degeneration/diagnosis; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Ranibizumab; Safety; Visual Acuity; Vitreous Body/drug effects

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Immunoglobulin Fragments / Choroidal Neovascularization / Vascular Endothelial Growth Factor A / Macular Degeneration / Antibodies, Monoclonal Type of study: Clinical_trials / Diagnostic_studies / Etiology_studies / Observational_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Year: 2005 Type: Article

Search on Google

XML

PubMed Links